Bionote announced on the 27th that it has decided to cancel 650,000 common shares.
The planned cancellation amount is 3,685.5 billion won, and the company will use treasury shares previously acquired. The scheduled cancellation date is March 6.
This cancellation will be carried out in accordance with the Commercial Act, with the board of directors resolving to cancel treasury shares obtained within the scope of distributable profits. As a result, only the total number of issued shares will decrease, while the capital stock will remain unchanged.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

